Table 2.
Ongoing clinical trials on the investigational drug candidates.
| Investigational Drug Candidate | NCT Number | Official Title | Phase |
|---|---|---|---|
| Umifenovir (Arbidol) | NCT04350684 | Efficacy and Safety of Umifenovir as an Adjuvant Therapy Compared to the Control Therapeutic Regiment of Interferon Beta 1a, Lopinavir/Ritonavir and a Single Dose of Hydroxychloroquine in Moderate to Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial | 4 |
| NCT04260594 | Randomized, Open, Multicenter Study on the Efficacy and Safety of Arbidol Hydrochloride Tablets in Treating Pneumonia in Patients Infected With Novel Coronavirus (2019-ncov) | 4 | |
| Remdesivir | NCT04292899 | A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe COVID-19 | 3 |
| NCT04292730 | A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment | 3 | |
| NCT04252664 | A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Mild and Moderate COVID-19 | 3 | |
| NCT04409262 | A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Patients With Severe COVID-19 Pneumonia | 3 | |
| NCT04257656 | A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Severe COVID-19 | 3 | |
| NCT04401579 | A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-II) | 3 | |
| NCT04330690 | A Multi-center, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO: Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization) | 2 | |
| NCT04280705 | A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults | 3 | |
| NCT04321616 | The (Norwegian) NOR Solidarity Multicenter Trial on the Efficacy of Different Anti-viral Drugs in SARS-CoV-2 Infected Patients | 3 | |
| NCT04315948 | Multi-center, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults | 3 | |
| NCT04349410 | The Fleming [FMTVDM] Directed COVID-19 Treatment Protocol | 2, 3 | |
| Favipiravir | NCT04336904 | A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Patients With COVID-19-Moderate Type | 3 |
| NCT04358549 | Open Label, Randomized, Controlled Phase 2 Proof-of-Concept Study of the Use of Favipiravir v. Standard of Care in Hospitalized Subjects With COVID-19 | 2 | |
| NCT04359615 | Efficacy and Safety of Favipiravir Compared to the Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized, Controlled, Double-Blind, Clinical Trial | 4 | |
| NCT04425460 | A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Adult Patients With COVID-19-Moderate Type | 3 | |
| NCT04349241 | Efficacy and Safety of Favipiravir in Management of COVID-19 | 3 | |
| NCT04402203 | Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh | 2 | |
| NCT04411433 | An Open-Label, Multicenter, Parallel-Group, Randomized, Phase III Study to Evaluate the Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19 | 3 | |
| NCT04387760 | Treatment of Covid-19 With Favipiravir Versus Hydroxychloroquine: a Randomized Comparator Trial | 3 | |
| NCT04392973 | A Trial of Favipiravir and Hydroxychloroquine Combination in Adults Hospitalized With Moderate and Severe Covid-19 | Not Applicable | |
| NCT04303299 | A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopinavir/Ritonavir Plus Oseltamivir Versus Darunavir/Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopinavir/Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopinavir/Ritonavir Versus Darunavir/Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19 | 3 | |
| NCT04310228 | Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study | Not Applicable | |
| NCT04376814 | The Regimen of Favipiravir Plus Hydroxychloroquine Can Accelerate Recovery of the COVID-19 Patients With Moderate Severity in Comparison to Lopinavir/Ritonavir Plus Hydroxychloroquine Regimen: an Open-label, Non-randomized Clinical Trial Study | Not Applicable | |
| NCT04333589 | The Mechanism, Clinical Outcome and Therapeutic Intervention of Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive | Not Applicable | |
| NCT04373733 | A Randomized Controlled Trial of Early Intervention in Patients Hospitalized With COVID-19: Favipiravir Verses Hydroxychloroquine & Azithromycin & Zinc verses Standard Care | 3 | |
| NCT04351295 | Clinical Study Evaluating the Efficacy of Favipiravir in COVID-19 Treatment | 2 | |
| NCT04346628 | A Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Favipiravir Compared to Current Standard of Care in Subjects With Mild or Asymptomatic COVID-19 | 2 | |
| NCT04356495 | Outpatient Treatment of Elderly People With Symptomatic SARS-CoV-2 Infection (COVID-19): a Multi-arm, Multi-stage (MAMS) Randomized Trial to Assess the Efficacy and Safety of Several Experimental Treatments to Decrease the Risk of Hospitalization or Death (COVERAGE Trial) | 3 | |
| NCT04345419 | The Results of COVID 19 Treatment: A Real-life Experience on Patients With COVID 19 | 3 | |
| Ribavirin | NCT04356677 | An Open-Label Study to Evaluate the Safety and Efficacy of VIRAZOLE® (RIBAVIRIN FOR INHALATION SOLUTION, USP) in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19 | 1 |
| NCT04392427 | Effect of a Combination of Nitazoxanide, Ribavirin and Ivermectin Plus Zinc Supplement on the Clearance of COVID-19: a Pilot Sequential Clinical Trial | 3 | |
| NCT04276688 | An Open-label Randomized Controlled Trial on Lopinavir/Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir/Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection | 2 | |
| Lopinavir/ritonavir | NCT04307693 | Randomized Controlled Clinical Trials of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19) | 2 |
| NCT04330690 | A Multi-center, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO: Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization) | 2 | |
| NCT04346147 | Prospective, Phase II, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Hydroxychloroquine Together With Baricitinib, Imatinib or Early Lopinavir/Ritonavir in Patients With SARS Cov 2 Pneumonia | 2 | |
| NCT04372628 | Trial of Early Therapies During Non-hospitalized Outpatient Window (TREAT NOW) for COVID-18 | 2 | |
| NCT04328285 | Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers: A Randomized Double-blind Placebo-controlled Clinical Trial | 3 | |
| NCT04359095 | Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia: A Pragmatic Randomized Controlled Trial | 3 | |
| NCT04409483 | Evaluation of Additional Treatments for COVID-19: a Randomized Trial in Niger | 3 | |
| NCT04403100 | Hydroxychloroquine and Lopinavir/Ritonavir for Hospitalization and Mortality Reduction in Patients With COVID-19 and Mild Disease Symptoms: “The Hope Coalition" | 3 | |
| NCT04321174 | COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir | 3 | |
| NCT04255017 | An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs (Arbidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) in the Treatment of 2019-nCoV Pneumonia | 4 | |
| NCT04364022 | Efficacy of Pragmatic Same-day Ring COVID-19 Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland: an Open-label Cluster Randomized Trial | 3 | |
| NCT04328012 | Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic adaptive randomized Clinical Trial During the COVID-19 Pandemic (COVID MED Trial) | 2 | |
| NCT04295551 | Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe) | Not Applicable | |
| NCT04321993 | Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients | 2 | |
| NCT04351724 | A Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2) | 3 | |
| NCT04365582 | A Randomized Trial of Efficacy and Safety of an Early Outpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome: a Strategy to Prevent Hospitalization | 3 | |
| NCT04315948 | Multi-center, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults | 3 | |
| NCT04386070 | Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19 | 3 | |
| NCT04381936 | Randomized Evaluation of COVID-19 Therapy | 2 | |
| NCT02735707 | Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia | 4 | |
| NCT04276688 | An Open-label Randomized Controlled Trial on Lopinavir/Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir/Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection | 2 | |
| NCT04303299 | A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopinavir/Ritonavir Plus Oseltamivir Versus Darunavir/Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopinavir/Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopinavir/Ritonavir Versus Darunavir/Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19 | 3 | |
| Camostat mesylate | NCT04353284 | The Effect of Camostat Mesylate on COVID-19 Infection in Ambulatory Patients: An Investigator-Initiated Randomized, Placebo-Controlled, Phase IIa Trial | 2 |
| NCT04321096 | The Impact of Camostat Mesilate on COVID-19 Infection: An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial | 1 | |
| NCT04338906 | Evaluation of the Efficacy and Safety of Camostat Mesilate + Hydroxychloroquine Combination Therapy in Hospitalized Patients With Moderate COVID-19 Infection | 4 | |
| NCT04374019 | Randomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive Patients | 2 |